Clarivate Plc Ordinary Shares (CLVT) Covered Calls

Clarivate PLC is a leading global provider of transformative intelligence, offering enriched data, insights, and analytics across the innovation lifecycle. The company operates through specialized segments in Academia and Government, Intellectual Property, and Life Sciences and Healthcare. By combining proprietary datasets with AI-driven workflow solutions, Clarivate enables organizations to discover, protect, and commercialize their most valuable ideas and scientific research.

You can sell covered calls on Clarivate Plc Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CLVT (prices last updated Tue 4:16 PM ET):

Clarivate Plc Ordinary Shares (CLVT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.35 +0.67 2.32 2.33 44.9M - 1.1
Covered Calls For Clarivate Plc Ordinary Shares (CLVT)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 2.5 0.10 2.23 4.5% 65.7%
Apr 17 2.5 0.15 2.18 6.9% 47.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Clarivate PLC (CLVT) is a global information services giant that provides the critical data and analytical tools required to power world-class innovation. Headquartered in London, the company serves as an essential partner to thousands of universities, law firms, and pharmaceutical companies. Its business model is centered on a high-margin, recurring revenue structure, where users subscribe to flagship platforms such as Web of Science for academic research, Derwent for patent intelligence, and Cortellis for life sciences drug development data.

The company’s value proposition lies in its ability to synthesize fragmented global information into actionable intelligence. In the IP segment, it manages millions of patents and trademarks through its specialized IPfolio and CompuMark software. In early 2026, the company accelerated its "Intelligence Amplified" initiative, deploying the Clarivate Nexus AI assistant. This tool allows researchers and IP professionals to use natural language to query billions of proprietary data points, significantly reducing the manual labor involved in literature reviews and patent landscapes.

Competitive Landscape

The competitive landscape for Clarivate consists of diversified B2B information providers and specialized research firms. Primary rivals that are publicly traded on the NYSE or NASDAQ and offer active options markets include Thomson Reuters Corporation and RELX PLC (LexisNexis). These entities compete for market share in the lucrative legal, academic, and scientific database sectors.

Other notable competitors in the clinical and data analytics sectors with active options trading include IQVIA Holdings Inc. and FactSet Research Systems Inc.. While smaller, niche competitors focus on specific geographic or industrial subsets, Clarivate distinguishes itself through its unmatched scale in the "Top 100 Global Innovators" index and its deep ownership of the "Impact Factor" metric, which remains the gold standard for measuring scientific journal quality. This systemic integration into the academic and corporate hierarchy creates high switching costs for its enterprise client base.

Strategic Outlook

Strategic innovation is currently focused on the full redemption of legacy debt and the optimization of its capital structure. By early 2026, the company has completed the redemption of $100 million in senior secured notes, shifting its focus toward aggressive share buybacks and organic revenue growth inflection. The launch of "Drugs to Watch 2026" and related AI-powered predictive reports is part of a broader push to move the company from being a data repository to a strategic consultant for the global pharmaceutical and biotech industries.

The outlook involves a push for margin expansion through the consolidation of its diverse software brands into a unified, cloud-native "One Clarivate" platform. Management is prioritizing investments in "Agentic AI" that can automate complex patent renewals and regulatory filings, aiming to offset pressures from open-access data alternatives. By maintaining a disciplined approach to its Value Creation Plan and leveraging its proprietary Derwent World Patents Index, the company aims to solidify its position as the premier infrastructure provider for the global knowledge economy.